TCL Archive Von Eschenbach takes leave of absence from NCI, resigns from C-Change board. Acting FDA commissioner’s drug approval strategy rooted in unproven science. Von Eschenbach told NCI deputies he might drop in on meetings. Who’s really in charge? October 7, 2005
TCL Archive NCI Pulls Back Curtain on “Zone of Uncertainty” — Funding Patterns Released With Little Comment May 4, 2012
TCL Archive DCT Board Pediatric Phase 1 Studies, Effort to Assess Obstacles To Clinical Trials July 6, 1984
TCL Archive Anastrozole Better Than Tamoxifen For HR+ Postmenopausal Breast Cancer, Study Finds May 27, 2005
TCL Archive FDA Says Bristol’s UFT “Not Approvable” For Colorectal Cancer, Contrary To ODAC. March 30, 2001
